Development of the standards of reporting of neurological disorders (STROND) checklist: A guideline for the reporting of incidence and prevalence studies in neuroepidemiology

European Journal of Epidemiology

Volumn 30, Issue 7, 2015, Pages 569-576

  Bennett, Derrick A ^a   Brayne, Carol ^b   Feigin, Valery L ^c   Barker Collo, Suzanne ^d   Brainin, Michael ^e   Davis, Daniel ^f   Gallo, Valentina ^g   Jetté, Nathalie ^h   Karch, André ⁱ   Kurtzke, John F ^j   Lavados, Pablo M ^k,l   Logroscino, Giancarlo ^m,n   Nagel, Gabriele ^o   Preux, Pierre Marie ^p   Rothwell, Peter M ^q   Svenson, Lawrence W ^r  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c AUCKLAND UNIVERSITY OF TECHNOLOGY   (New Zealand)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

^e DANUBE UNIVERSITY KREMS   (Austria)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^h UNIVERSITY OF CALGARY   (Canada)

ⁱ HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^j GEORGETOWN UNIVERSITY   (United States)

^k UNIVERSIDAD DEL DESARROLLO   (Chile)

^l UNIVERSITY OF CHILE   (Chile)

^m UNIVERSITY OF BARI   (Italy)

ⁿ UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^o UNIVERSITY OF ULM   (Germany)

^p UNIVERSITÉ DE LIMOGES   (France)

^q UNIVERSITY OF OXFORD   (United Kingdom)

^r UNIVERSITY OF ALBERTA   (Canada)

more..

Author keywords

Checklist; Epidemiology; Incidence; Neurology; Prevalence; Reporting

Indexed keywords

ARTICLE; CHECKLIST; CONSULTATION; DELPHI STUDY; HUMAN; INCIDENCE; NEUROLOGIC DISEASE; PRACTICE GUIDELINE; PREVALENCE; SYSTEMATIC REVIEW; CONSENSUS; INFECTION CONTROL; MANDATORY REPORTING; NERVOUS SYSTEM DISEASES; PROCEDURES; STANDARDS;

CHECKLIST; CONSENSUS; DELPHI TECHNIQUE; DISEASE NOTIFICATION; GUIDELINES AS TOPIC; HUMANS; INCIDENCE; MANDATORY REPORTING; NERVOUS SYSTEM DISEASES; PREVALENCE;

EID: 84943347767     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-015-0034-5     Document Type: Article

References (26)

1. Whiteford HA, Ferrari AJ, Degenhardt L, Feigin V, Vos T. The global burden of mental, neurological and substance use disorders: an analysis from the global burden of disease study 2010. PLoS One. 2015; 10(2): e0116820.
2. Rao D, Choi S, Victorson D, Bode R, Peterman A, Heinemann A, et al. Measuring stigma across neurological conditions: the development of the stigma scale for chronic illness (SSCI). Qual Life Res. 2009; 18(5): 585-95.
3. Murray CJ, Ezzati M, Flaxman AD, Lim S, Lozano R, Michaud C, et al. GBD 2010: a multi-investigator collaboration for global comparative descriptive epidemiology. Lancet. 2013; 380(9859): 2055-8.
4. Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the "common" neurologic disorders? Neurology. 2007; 68(5): 326-37.
5. Albert SM. Projecting neurologic disease burden: difficult but critical. Neurology. 2007; 68(5): 322-3.
6. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2013; 380(9859): 2163-96.
7. Simera I, Moher D, Hirst A, Hoey J, Schulz KF, Altman DG. Transparent and accurate reporting increases reliability, utility, and impact of your research: reporting guidelines and the EQUATOR Network. BMC Med. 2010; 8: 24 Epub 2010/04/28.
8. Feigin V, Kurtzke JF, Korczyn A, Beghi E, Brown A. Bridging the gap between experimental and non-experimental neuroepidemiology, and ultimately-between neuroepidemiological research and practice: round table discussion at the First International Congress on Clinical Neurology and Epidemiology. Neuroepidemiology. 2009; 33(4): 296-304.
9. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. J Pharmacol Pharmacother. 2010; 1(2): 100-7.
10. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339: b2700.
11. Oermann MH. SQUIRE guidelines for reporting improvement studies in healthcare: implications for nursing publications. J Nurs Care Qual. 2009; 24(2): 91-5.
12. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007; 335(7624): 806-8 Epub 2007/10/20.
13. Chin JH, Vora N. The global burden of neurologic diseases. Neurology. 2014; 83(4): 349-51.
14. Evans C, Beland SG, Kulaga S, Wolfson C, Kingwell E, Marriott J, et al. Incidence and prevalence of multiple sclerosis in the Americas: a systematic review. Neuroepidemiology. 2013; 40(3): 195-210 Epub 2013/02/01.
15. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord. 2005; 20(10): 1255-63.
16. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007; 68(5): 384-6.
17. GBD 2013 Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 385(9963): 117-71.
18. Moher D, Schulz KF, Simera I, Altman DG. Guidance for developers of health research reporting guidelines. PLoS Med. 2010; 7(2): e1000217 (Epub 2010/02/20).
19. Steurer J. The Delphi method: an efficient procedure to generate knowledge. Skeletal Radiol. 2011; 40(8): 959-61 Epub 2011/06/15.
20. Hopewell S, Ravaud P, Baron G, Boutron I. Effect of editors' implementation of CONSORT guidelines on the reporting of abstracts in high impact medical journals: interrupted time series analysis. BMJ. 2012; 344: e4178 Epub 2012/06/26.
21. Turner L, Shamseer L, Altman D, Schulz K, Moher D. Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane reviewa. Syst Rev. 2012; 1(1): 60.
22. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010; 340: c869 Epub 2010/03/25.
23. Altman DG, Simera I, Hoey J, Moher D, Schulz K. EQUATOR: reporting guidelines for health research. Lancet. 2008; 371(9619): 1149-50 Epub 2008/04/09.
24. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. The EQUATOR Network and reporting guidelines: Helping to achieve high standards in reporting health research studies. Maturitas. 2009; 63(1): 4-6 Epub 2009/04/18.
25. Cialkowska M, Adamowski T, Piotrowski P, Kiejna A. What is the Delphi method? Strengths and shortcomings. Psychiatria polska. 2008; 42(1): 5-15 (Epub 2008/06/24. Czym jest metoda Delphi? Zalety i ograniczenia).
26. Murray CJ, Ezzati M, Flaxman AD, Lim S, Lozano R, Michaud C, et al. GBD 2010: design, definitions, and metrics. Lancet. 2013; 380(9859): 2063-6.